NGS Companion Diagnostics: The Backbone of Precision Oncology in 2026
by 21Stable Team
March 2026 marks a turning point in personalized cancer medicine: Within just three weeks, the FDA approved several Next-Generation Sequencing (NGS)-based companion diagnostics—and signaled a paradigm shift toward broader biomarker-driven therapy decisions.
Current FDA Approvals Overview
Zongertinib and HER2-Mutant NSCLC
On February 26, 2026, the FDA granted accelerated approval for Zongertinib (trade name Hernexeos) for the treatment of HER2-mutant non-small cell lung cancer (NSCLC) in treatment-naive patients. This marks the first targeted tyrosine kinase inhibitor therapy for this previously underserved patient population.
The approval was based on the Phase I/II SOHO-01 study, in which Zongertinib achieved an objective response rate (ORR) of **71% in Cohort D**—a remarkable figure for a population that previously had limited options beyond platinum-based chemotherapy or PD-L1 inhibitors with limited success.
EGFR Exon 20 and NGS Companion Diagnostics
Just a few days later, on March 18, 2026, the FDA expanded the indication of the Oncomine Dx Target Test and Oncomine Dx Express Test as companion diagnostics for EGFR Exon 20 insertion mutations in NSCLC. These tests now enable identification of patients eligible for treatment with Sunvozertinib (Sevabertinib).
The Oncomine Dx Target Test is already approved for **six targeted therapies in NSCLC and one in cholangiocarcinoma**, covering one of the broadest biomarker palettes in thoracic oncology.
MI Cancer Seek: Whole-Exome and Whole-Transcriptome
Also in March 2026, MI Cancer Seek received FDA approval as the first diagnostic assay combining **whole-exome sequencing (WES) with whole-transcriptome sequencing (WTS)**. The test identifies genetic alterations in **228 genes**, including MSI and Tumor Mutational Burden (TMB).
This approval marks a technological milestone: moving from focused gene panels toward comprehensive genomic profiling in clinical routine.
The Statistical Reality: What the Data Shows
Actionable Variants in Over 72%
A recent joint study by LabCorp and Illumina from March 2026, analyzing over **7,600 NSCLC samples**, found actionable genetic variants—alterations that enable targeted therapeutic intervention—in **more than 72% of cases**.
This figure underscores the clinical utility of broad genomic testing: in nearly three-quarters of all NSCLC patients, there exists a therapy-relevant mutation that would remain undetected without NGS diagnostics.
The Panel Gap: Only 5 of 77 Capture All Recommended Biomarkers
A recent analysis published in the American Journal of Managed Care evaluated commercial NGS panels and revealed a concerning gap: Of **77 evaluated panels**, only **5 captured all NCCN-guideline-recommended biomarkers** for metastatic NSCLC.
The implication is clear: The choice of NGS panel is a therapy-relevant decision. An incomplete panel can result in patients not receiving optimal targeted therapy.
Market Structure: Companion Diagnostics as a Growth Market
The oncology companion diagnostics market is projected to reach **$17.26 billion by 2035** according to current forecasts. Driving forces include:
Clinical Implications for Biostatisticians
Test Selection as a Statistical Decision
The choice of adequate NGS panel is not purely logistical but a statistical decision with direct implications for:
Real-World Evidence Integration
The LabCorp-Illumina study demonstrates the value of real-world data (RWD) for validating genomic testing strategies. Biostatisticians should:
Outlook: The Evolution of the Biomarker Landscape
Frontiers in Oncology published on March 11, 2026, a comprehensive review of the evolving biomarker landscape in NSCLC. The authors identified several emerging biomarkers beyond classical drivers:
The integration of these markers into clinical decision pathways increasingly requires **multivariate statistical models** that account for complex interactions between genetic, immunological, and clinical factors.
Conclusion
The FDA approvals of Q1 2026 demonstrate the transition of NGS-based companion diagnostics from a specialized instrument to clinical routine. The statistical evidence—over 72% actionability in large NSCLC cohorts—justifies broad genomic testing as the standard.
For biostatisticians in oncology, an increasingly important area of responsibility is emerging: The validation, integration, and interpretation of genomic data in clinical context. Choosing the right panel, integrating real-world evidence, and developing robust statistical frameworks for biomarker-driven therapy decisions will be core competencies of the coming years.
---
Key Findings
Statistical evidence supports broad genomic testing: a LabCorp-Illumina study of >7,600 NSCLC samples found actionable variants in >72% of cases. However, only 5 of 77 commercial NGS panels captured all guideline-recommended biomarkers.